The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Open accessAbstract
The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998-September 2002. Granulomatous infections were reported at rates of approximately 239 per 100,000 patients who received infliximab and approximately 74 per 100,000 patients who received etanercept (P<.001). Tuberculosis was the most frequently reported disease, occurring in approximately 144 and approximately 35 per 100,000 infliximab-treated and etanercept-treated patients, respectively (P<.001). Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and infections due to nontuberculous mycobacteria were reported with significantly greater frequency among infliximab-treated patients. Seventy-two percent of these infection occurred < or =90 days after starting infliximab treatment, and 28% occurred after starting etanercept treatment (P<.001). These data indicate a risk of granulomatous infection that was 3.25-fold greater among patients who received infliximab than among those who received etanercept. The clustering of reports shortly after initiation of treatment with infliximab is consistent with reactivation of latent infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
Roach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., & Britton, W. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4620 · Cited by 782
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
(2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441415 · Cited by 330
Siegel, S. A., Shealy, D. J., Nakada, M. T., Le, J., Woulfe, D. S., Probert, L., Kollias, G., Ghrayeb, J., Vilcek, J., & Daddona, P. E. (1995) · Cytokine · doi:10.1006/cyto.1995.1003 · Cited by 222
Cited by
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Hidradenitis suppurativa: A comprehensive review
Alikhan, A., Lynch, P. J., & Eisen, D. B. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.911 · Cited by 705
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Strategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
NETWORK COMMUNICATIONS: Lymphotoxins, LIGHT, and TNF
Ware, C. F. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115719 · Cited by 441
Macrophage and T Cell Dynamics during the Development and Disintegration of Mycobacterial Granulomas
Egen, J. G., Rothfuchs, A. G., Feng, C. G., Winter, N., Sher, A., & Germain, R. N. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.010 · Cited by 356
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
Life and death in the granuloma: immunopathology of tuberculosis
Saunders, B. M., & Britton, W. J. (2007) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100027 · Cited by 340
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Tsiodras, S., Samonis, G., Boumpas, D. T., & Kontoyiannis, D. P. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60839-2 · Cited by 331
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F., & LoBue, P. A. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1510.090310 · Cited by 320
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.014 · Cited by 316
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Bruns, H., Meinken, C., Schauenberg, P., Härter, G., Kern, P., Modlin, R. L., Antoni, C., & Stenger, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38482 · Cited by 307
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Listeria monocytogenes: epidemiology, human disease, and mechanisms of brain invasion
Drevets, D. A., & Bronze, M. S. (2008) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2008.00404.x · Cited by 303
Donahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B. L., Hansen, R. A., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00192 · Cited by 299
How tumour necrosis factor blockers interfere with tuberculosis immunity
Harris, J., & Keane, J. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04146.x · Cited by 291
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic
Keane, J. (2005) · Rheumatology · doi:10.1093/rheumatology/keh567 · Cited by 281
Winthrop, K. L. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0336 · Cited by 280
Scott Algood, H. M., Lin, P. L., & Flynn, J. L. (2005) · Clinical Infectious Diseases · doi:10.1086/429994 · Cited by 278
Sfikakis, P. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289205 · Cited by 275
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Self-citationSmith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D., Finlay, A. Y., Grifitths, C. E. M., Jackson, K., McHugh, N. J., et al. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06893.x · Cited by 275
Mycobacterial diseases and antitumour necrosis factor therapy in USA
Winthrop, K., Baxter, R., Liu, L., Varley, C., Curtis, Jr., Baddley, J., McFarland, B., Austin, D., Radcliffe, L., Suhler, E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200690 · Cited by 274
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Antirheumatic Drugs and the Risk of Tuberculosis
Brassard, P., Kezouh, A., & Suissa, S. (2006) · Clinical Infectious Diseases · doi:10.1086/506935 · Cited by 266
Systemic Histoplasmosis: A 15-Year Retrospective Institutional Review of 111 Patients
Assi, M. A., Sandid, M. S., Baddour, L. M., Roberts, G. D., & Walker, R. C. (2007) · Medicine · doi:10.1097/md.0b013e3180679130 · Cited by 261
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Interleukin-18 and the Pathogenesis of Inflammatory Diseases
Dinarello, C. A. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2006.09.013 · Cited by 252
Targeting monocytes/macrophages in the treatment of rheumatoid arthritis
Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., & Cantagrel, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes304 · Cited by 209
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
DINARELLO, C. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.010 · Cited by 195
Reconsidering Adjuvant Immunotherapy for Tuberculosis
Wallis, R. S. (2005) · Clinical Infectious Diseases · doi:10.1086/430914 · Cited by 121
Self-citationMerkhofer, R. M., O’Neill, M. B., Xiong, D., Hernandez-Santos, N., Dobson, H., Fites, J. S., Shockey, A. C., Wuethrich, M., Pepperell, C. S., & Klein, B. S. (2019) · mBio · doi:10.1128/mbio.01224-19 · Cited by 39
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-05-01
- Volume
- 38
- Issue
- 9
- Pages
- 1261-1265
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2114872119
- Cited by
- 977
- References
- 16
- FWCI
- 38.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.